The combination of amivantamab and lazertinib has shown to halt the advancement of lung cancer for an average of 23.7 months, outperforming the standard treatment.
This new combination demonstrates longer cancer control compared to osimertinib, which itself was a breakthrough just a few years ago, prompting optimism among cancer experts.
A better understanding of the biology behind lung cancers is facilitating targeted treatments, particularly in advanced stages where survival rates are usually low.
Collection
[
|
...
]